JP6339668B2 - 細胞動員に使用するデキストラン硫酸 - Google Patents

細胞動員に使用するデキストラン硫酸 Download PDF

Info

Publication number
JP6339668B2
JP6339668B2 JP2016513900A JP2016513900A JP6339668B2 JP 6339668 B2 JP6339668 B2 JP 6339668B2 JP 2016513900 A JP2016513900 A JP 2016513900A JP 2016513900 A JP2016513900 A JP 2016513900A JP 6339668 B2 JP6339668 B2 JP 6339668B2
Authority
JP
Japan
Prior art keywords
dextran sulfate
subject
cells
csf
mobilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016513900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519143A5 (https=
JP2016519143A (ja
Inventor
ワーズ，アンダーズ
デュプレズ，イダ
Original Assignee
ティーエックス メディック エービー
ティーエックス メディック エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティーエックス メディック エービー, ティーエックス メディック エービー filed Critical ティーエックス メディック エービー
Publication of JP2016519143A publication Critical patent/JP2016519143A/ja
Publication of JP2016519143A5 publication Critical patent/JP2016519143A5/ja
Application granted granted Critical
Publication of JP6339668B2 publication Critical patent/JP6339668B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016513900A 2013-05-13 2014-05-12 細胞動員に使用するデキストラン硫酸 Expired - Fee Related JP6339668B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350584A SE537742C2 (sv) 2013-05-13 2013-05-13 Dextransulfat för cellmobilisering
SE1350584-7 2013-05-13
PCT/SE2014/050576 WO2014185851A1 (en) 2013-05-13 2014-05-12 Dextran sulfate for use in mobilization of cells

Publications (3)

Publication Number Publication Date
JP2016519143A JP2016519143A (ja) 2016-06-30
JP2016519143A5 JP2016519143A5 (https=) 2017-06-22
JP6339668B2 true JP6339668B2 (ja) 2018-06-06

Family

ID=51898693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016513900A Expired - Fee Related JP6339668B2 (ja) 2013-05-13 2014-05-12 細胞動員に使用するデキストラン硫酸

Country Status (10)

Country Link
US (1) US10258642B2 (https=)
EP (1) EP2999478B1 (https=)
JP (1) JP6339668B2 (https=)
CN (1) CN105358159B (https=)
CA (1) CA2912366C (https=)
DK (1) DK2999478T3 (https=)
ES (1) ES2780907T3 (https=)
PL (1) PL2999478T3 (https=)
SE (1) SE537742C2 (https=)
WO (1) WO2014185851A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
SE538503C2 (en) * 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
RU2623152C9 (ru) * 2015-10-15 2022-02-17 Акционерное общество "Федеральный научно-производственный центр "Алтай" Композиция, обладающая гепатопротекторными и иммуностимулирующими свойствами
CN114127262A (zh) * 2019-05-16 2022-03-01 香港中文大学 细胞外基质材料及其用途
SE544015C2 (en) * 2019-06-18 2021-11-02 Tx Medic Ab Allogenic car-t cell therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454560A (en) 1966-03-01 1969-07-08 Seikagaku Kogyo Co Ltd Process for the production of chondroitin polysulfate
SE525461C3 (sv) 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat
CN1589904A (zh) 2003-09-01 2005-03-09 北京大学 造血干细胞动员剂制备治疗糖尿病药物的用途

Also Published As

Publication number Publication date
CN105358159B (zh) 2018-08-28
EP2999478B1 (en) 2020-01-15
CA2912366A1 (en) 2014-11-20
EP2999478A1 (en) 2016-03-30
CA2912366C (en) 2021-04-06
DK2999478T3 (da) 2020-04-14
EP2999478A4 (en) 2017-02-22
WO2014185851A1 (en) 2014-11-20
US10258642B2 (en) 2019-04-16
US20160120897A1 (en) 2016-05-05
PL2999478T3 (pl) 2020-10-19
SE1350584A1 (sv) 2014-11-14
ES2780907T3 (es) 2020-08-27
CN105358159A (zh) 2016-02-24
BR112015028270A2 (pt) 2017-07-25
JP2016519143A (ja) 2016-06-30
SE537742C2 (sv) 2015-10-13

Similar Documents

Publication Publication Date Title
US20200268850A1 (en) Methods and compositions for mobilizing stem cells
JP6189911B2 (ja) （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の組合せ使用
EP2324109B1 (en) Expansion of haemopoietic precursors
JP6339668B2 (ja) 細胞動員に使用するデキストラン硫酸
US20140294755A1 (en) Materials and Methods Relating to Stem Cell Mobilization by Multi-Pegylated Granulocyte Colony Stimulating Factor
RU2351357C2 (ru) Фармацевтическая композиция, используемая для мобилизации стволовых клеток
KR102376846B1 (ko) 수지상 세포를 함유하는 의약 및 그 제조 방법
Bregni et al. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
US20110076247A1 (en) Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy
KR20230133317A (ko) 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염
Hayakawa et al. Dextran sulfate and stromal cell derived factor-1 promote CXCR4 expression and improve bone marrow homing efficiency of infused hematopoietic stem cells
US12162918B2 (en) Periostin compounds for the treatment of haematological complications
Mullen et al. Clinical uses of recombinant haematopoietic growth factors in paediatrics
TW201121965A (en) Use of a quinolone derivative containing 7-(4-aminomethyl-3-oxime)pyrrolidine group that is capable of inducing granulocyte colony stimulating factor for treatment of neutropenia and recovery of hematopoiesis
BR112015028270B1 (pt) Composição de mobilização de células para uso na mobilização de células progenitoras e/ou células tronco
US20240082356A1 (en) Treatment of copd by stimulation of stem cell mobilization
JP2024517954A (ja) 肝疾患を治療するための方法および組成物
WO2025076042A1 (en) Mesenchymal stem cell-mediated treatments for the prevention and targeted treatment of injured tissues and promotion of tissue repair, healing, and regeneration
KR20260040708A (ko) Ccl5를 포함하는 골수 유래 줄기세포의 활성화 촉진용 조성물
JP2023515502A (ja) Ｃｏｖｉｄ－１９を治療するための早期アポトーシス細胞の使用
Chari et al. Feasibility of Cd34-positive stem cell mobilization by administration of AMD3100 six hours prior to leukapheresis
Milwid Discovery of novel anti-inflammatory proteins inspired by bone marrow mesenchymal stem cell secretions
Wick et al. Disturbances of Iron Distribution and Hypochromic Anemias
JPWO2018225848A1 (ja) 敗血症の予防又は治療用組成物
WO2014021682A1 (ko) CD11b+ CX3CR1+ 세포, 이의 이용 및 이의 대량 수집 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180510

R150 Certificate of patent or registration of utility model

Ref document number: 6339668

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees